Price Target Update on Galena Biopharma (NASDAQ:GALE)

Galena Biopharma (NASDAQ:GALE) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $5 and the lowest price target forecast is $2. The average forecast of all the analysts is $3.9 and the expected standard deviation is $1.25.

Other Equity analysts have also commented on the company shares. Roth Capital maintains their rating on the shares of Galena Biopharma (NASDAQ:GALE). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $5 per share from $6 per share. The rating by the firm was issued on March 11, 2016.

Galena Biopharma (NASDAQ:GALE): On Thursdays trading session , Opening price of the stock was $2.3 with an intraday high of $2.31. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $1.93. However, the stock managed to close at $2.15, a loss of 5.29% for the day. On the previous day, the stock had closed at $2.27. The total traded volume of the day was 5,195,253 shares.

The company shares have rallied 24.04% from its 1 Year high price. On Jun 20, 2016, the shares registered one year high at $2.49 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $1.76 and the 200 Day Moving Average price is recorded at $1.29. On the companys insider trading activities, The officer (Former Chief Financial Officer), of Galena Biopharma, Inc., Dunlap Ryan had unloaded 126,875 shares at $2.18 per share in a transaction on June 1, 2016. The total value of transaction was $276,588. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.